Please ensure Javascript is enabled for purposes of website accessibility

Why Agenus Stock Is Marching Higher Today

By George Budwell - Jun 17, 2021 at 12:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech took a major step toward becoming a commercial-stage cancer company.

What happened

Shares of the small-cap immunotherapy company Agenus (AGEN 3.52%) were up by a healthy 9.98% as of 11:08 a.m. EDT Thursday morning. The biotech's stock is rising today in response to the Food and Drug Administration's acceptance of the company's Biologics License Application (BLA) for balstilimab.

Balstilimab is an anti-PD-1 antibody indicated for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The FDA reportedly set a target action date of Dec. 16, 2021, for the experimental cancer treatment.

Close up image of cancer cells.

A close-up of cancer cells. Image source: Getty Images.

So what

An approval would arguably go a long way toward validating Agenus' long and winding pivot to cancer treatments as its main value driver. What's important to understand is that the company started down this road over seven years ago, and this BLA marks Agenus' first regulatory filing from this effort.

Moreover, Wall Street has never loved this strategy due to the fact that the checkpoint inhibitor space is a tough place to make a living, given the intense level of competition. Balstilimab's upcoming regulatory review, though, could be the catalyst that finally changes the narrative around the company's cancer-treatment pipeline, as well as its stock. 

Now what

Can Agenus' shares push even higher? That's a definite yes for a multitude of reasons.

Apart from the maturation of its cancer-treatment pipeline, Agenus recently inked a lucrative development deal with Bristol Myers Squibb. This sizable deal could prove to be a prelude to a buyout.

What's more, the company has multiple clinical and regulatory catalysts coming up over the next year. Aggressive investors, therefore, might want to check out this intriguing biotech growth stock soon. 

 

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agenus Inc. Stock Quote
Agenus Inc.
AGEN
$2.65 (3.52%) $0.09
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$72.12 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.